Considering the efficacy of both ERL and SAP in inhibiting the activities of ERBB receptors in EML4-ALK-driven NSCLC cells, we next hypothesized that their pronounced anti-proliferative activity could sensitize the LOR-resistant (LOR R) H2228 cells. The gene discussed is EML4; the disease is non-small cell lung carcinoma.